Evaluation of Blood Loss and Pain in TKA With and Without Pneumatic Tourniquet, A Randomized Controlled Trial

Sponsor
Assiut University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05144425
Collaborator
(none)
100
2
11.7

Study Details

Study Description

Brief Summary

The aim of our study is to determine whether the use of a tourniquet during TKA would affect total measured blood loss , operation time, postoperative complications; hemoglobin concentration; limb swelling and postoperative pain.

Condition or Disease Intervention/Treatment Phase
  • Procedure: total knee arthroplasty with and without using pneumatic tourniquet
N/A

Detailed Description

Tourniquets are widely used in total knee arthroplasty (TKA) . TKA has been reported to be associated with significant blood loss which at times necessitates transfusion. Although the tourniquet is widely used by orthopedic surgeons, its role is controversial . Several studies have shown that using a tourniquet in TKA could reduce the total blood loss, while results from others indicated the opposite . Therefore the relationship between the use of a tourniquet and the total blood loss of patients undergoing TKA is still unclear. The use of a tourniquet is believed to be effective for decreasing intraoperative blood loss and creating a bloodless surgical field, which theoretically would facilitate the cementing technique and other surgical procedures. However, reactive blood flow reaches its peak within five minutes after the tourniquet has been released Complications reported as a consequence of tourniquet application are skin injury [skin abrasions, blisters, breaks , pressure necrosis], nerve injury, post tourniquet syndrome, Deep venous thrombosis, Postoperative pain, wound healing disorders and early infections

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
Evaluation of Blood Loss and Pain in TKA With and Without Pneumatic Tourniquet, A Randomized Controlled Trial
Anticipated Study Start Date :
Dec 10, 2021
Anticipated Primary Completion Date :
Oct 1, 2022
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: group A

underwent TKA with using pneumatic tourniquet

Procedure: total knee arthroplasty with and without using pneumatic tourniquet
The randomization will be performed by a research fellow who will not be involved in patient care. All of the operations will be performed through the medial parapatellar approach by experienced knee surgeons. Drainage system will be used for 48 hours postoperative. In the tourniquet group, the tourniquet will be inflated to a pressure of systolic blood pressure plus 100 mm Hg and will be released after the joint capsule has been closed. hemostasis and then will be wrapped with elastic bandages. In the non-tourniquet group, the tourniquet will be wrapped around the thigh but will not be inflated during the surgery. The criterion for a blood transfusion will set as a hemoglobin (Hb) level of<8 g/dL or patient with symptomatic anemia.

Placebo Comparator: group B

underwent TKA without using pneumatic tourniquet

Procedure: total knee arthroplasty with and without using pneumatic tourniquet
The randomization will be performed by a research fellow who will not be involved in patient care. All of the operations will be performed through the medial parapatellar approach by experienced knee surgeons. Drainage system will be used for 48 hours postoperative. In the tourniquet group, the tourniquet will be inflated to a pressure of systolic blood pressure plus 100 mm Hg and will be released after the joint capsule has been closed. hemostasis and then will be wrapped with elastic bandages. In the non-tourniquet group, the tourniquet will be wrapped around the thigh but will not be inflated during the surgery. The criterion for a blood transfusion will set as a hemoglobin (Hb) level of<8 g/dL or patient with symptomatic anemia.

Outcome Measures

Primary Outcome Measures

  1. amount of perioperative blood loss in ml with and without using tourniquet during TKA [48hr]

    Total measured blood loss will be calculated as the volume of the intraoperative blood loss plus the volume of postoperative visible blood loss from the hemovac drains and will be expressed as mL

Secondary Outcome Measures

  1. post operative pain measured on VAS after TKA with and without using tourniquet [48hr]

    Knee joint pain will be measured on a visual analog scale (VAS) (range, 0-10) pre-operatively and on the 3rd, 5th, 7th and 14th postoperative days [12]. A higher score on the VAS equates to a higher level of pain.

  2. operative time in minutes with and without using tourniquet in TKA [operation time]

    operative time in minutes will be calculated and compared the two groups

  3. hemoglobin level in gm/dl preoperative and postoperative [48hrs]

    Hemoglobin level will be measured pre-operatively and after 24hrs and 48 hrs post-operatively. Patients with Hb < 8 g/dl or those who have exhibited symptoms of acute anemia will receive blood transfusion therapy. The amount of blood transfused will be recorded.

Eligibility Criteria

Criteria

Ages Eligible for Study:
55 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • any patient with knee osteoarthritis undergoing primary total knee arthroplasty
Exclusion Criteria:
  1. patients with hemorrhagic disease

  2. patient with revision total knee arthroplasty

  3. patient with history of vascular thrombosis

  4. patients taking anti-platelet agents due to cardiovascular disease

  5. patients with hemoglobin level below 10gm/dl

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Assiut University

Investigators

  • Study Chair: Mohamed Ahmed Mahran, MD, staff member at assuit university faculty of medicine orthopedic department

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
mohamed elbasel abd-elraheem, Assiut medical school ethical review board [assiut], Assiut University
ClinicalTrials.gov Identifier:
NCT05144425
Other Study ID Numbers:
  • Elbasel
First Posted:
Dec 3, 2021
Last Update Posted:
Dec 3, 2021
Last Verified:
Nov 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by mohamed elbasel abd-elraheem, Assiut medical school ethical review board [assiut], Assiut University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 3, 2021